Gibson James R II 4

What Happened
James R. Gibson II, Chief Financial Officer of Pacific Biosciences (PACB), sold 88,185 shares on April 1, 2026 in an open-market/private sale (code S). The weighted average sale price was $1.37 per share (range $1.35–$1.39), generating gross proceeds of approximately $120,813. The filing notes these shares were mandatorily sold to cover tax-withholding obligations related to vested restricted stock units (RSUs).

Key Details

• Transaction date: 2026-04-01; Form 4 filed 2026-04-03 (filed within the standard two-business-day reporting window).
• Shares sold: 88,185; weighted average price reported $1.37 (range $1.35–$1.39).
• Proceeds: ~$120,813.
• Footnotes: F1 — sale was a mandatory tax-withholding sale tied to RSU vesting; F2 — sale price is a weighted average across $1.35–$1.39, with per-price details available upon request.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No 10b5-1 plan or other trading arrangement was disclosed in the excerpt.

Context
This transaction appears to be a routine, mandatory sale to satisfy tax-withholding on vested awards rather than a discretionary cash-out by the CFO. Such withholding sales are common following RSU vesting and do not necessarily indicate management sentiment about the company's stock. Purchases by insiders tend to be more informative about bullish conviction; this filing documents a routine tax-related sale.